ArticleBritish journal of clinical pharmacology2026
Absolute bioavailability and intravenous pharmacokinetics of N-acetyl-D-mannosamine in humans.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Alternative Dosing Strategies to Enhance the Absorption of N-Acetyl-D-Mannosamine Monohydrate (ManNAc) in Healthy Adult Males.Clinical drug investigation · 2026Trial
- Absolute bioavailability and intravenous pharmacokinetics of N-acetyl-D-mannosamine in humans.British journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimsN-acetyl-D-mannosamine monohydrate (ManNAc) is a naturally occurring monosaccharide that has attracted considerable attention for its potential in treating GNE myopathy, a rare autosomal recessive muscle disorder. Despite its promise as an oral treatment, the absolute bioavailability of oral ManNAc has not been determined and there has been no evaluation of the ManNAc pharmacokinetics following intravenous administration in humans. The aim of this study was to investigate the pharmacokinetics of intravenous ManNAc and to characterize its absolute bioavailability following a single oral dose.
methodsIn this single-centre, open-label, crossover study, six healthy adult males were administered ManNAc as a single oral dose (1000 mg) and intravenous dose (100 mg). Blood samples were collected over a 48 h period after dose administration for the quantification of plasma ManNAc concentrations. Non-compartmental pharmacokinetic analysis was performed using baseline-corrected plasma concentration-time data.
resultsAfter intravenous dosing, the mean plasma clearance of ManNAc was 10.1 ± 1.94 L/h, volume of distribution was 24.1 ± 4.98 L and elimination half-life was 1.67 ± 0.251 h. The mean absolute bioavailability of oral ManNAc at a dose of 1000 mg was 4.01 ± 1.82%. Deconvolution analysis revealed a zero-order absorption rate of about 10 mg per hour in the initial 3 h after dosing.
conclusionsThe low oral bioavailability of ManNAc is likely due to poor absorption (rather than first-pass hepatic extraction) due to its high polarity. In addition, zero-order absorption explains why the systemic exposure to ManNAc does not increase proportionally with dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.